Moderna Valuation
Is M1RN34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of M1RN34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate M1RN34's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate M1RN34's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for M1RN34?
Key metric: As M1RN34 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is M1RN34's PS Ratio? | |
|---|---|
| PS Ratio | 3.1x |
| Sales | US$5.08b |
| Market Cap | US$15.82b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.6x |
| Enterprise Value/EBITDA | -3.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does M1RN34's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.1x | ||
BLAU3 Blau Farmacêutica | 1.5x | 11.7% | R$2.6b |
BIOM3 Biomm | 9.1x | n/a | R$1.1b |
603392 Beijing Wantai Biological Pharmacy Enterprise | 37.2x | 60.9% | CN¥92.6b |
BNTX BioNTech | 8.6x | 3.4% | US$27.1b |
M1RN34 Moderna | 3.1x | 6.8% | R$15.8b |
Price-To-Sales vs Peers: M1RN34 is good value based on its Price-To-Sales Ratio (3.1x) compared to the peer average (14.1x).
Price to Sales Ratio vs Industry
How does M1RN34's PS Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: M1RN34 is good value based on its Price-To-Sales Ratio (3.1x) compared to the Global Biotechs industry average (8.9x).
Price to Sales Ratio vs Fair Ratio
What is M1RN34's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.1x |
| Fair PS Ratio | 2.1x |
Price-To-Sales vs Fair Ratio: M1RN34 is expensive based on its Price-To-Sales Ratio (3.1x) compared to the estimated Fair Price-To-Sales Ratio (2.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Novartis
CHF 187.3b
Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
N1VS34
CHF 60.90
7D
0.8%
1Y
26.5%
Blau Farmacêutica
R$2.6b
A pharmaceutical company provides high-complpexity drugs in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States.
BLAU3
R$14.70
7D
-1.5%
1Y
-8.4%
BeiGene
US$20.2b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
B1GN34
US$45.36
7D
0%
1Y
n/a